Odysight.Ai Inc. (ODYS) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Odysight.Ai Inc. (formerly ScoutCam Inc.) is a Nevada corporation providing image-based platform solutions for Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) markets, primarily serving aviation, transportation, energy, and healthcare sectors. The company operates as a smaller reporting company and is currently in a growth phase, focusing on Industry 4.0 (I4.0) applications.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $1.292 million | $0.110 million | $2.660 million | $1.087 million |
| Gross Profit | $0.405 million | ($0.211 million) | $0.696 million | ($0.561 million) |
| Operating Loss | ($3.016 million) | ($2.872 million) | ($8.744 million) | ($8.770 million) |
| Net Loss | ($2.867 million) | ($2.542 million) | ($8.211 million) | ($8.104 million) |
| Cash & Equivalents | $20.906 million (as of Sept 30, 2024) | |||
| Accumulated Deficit | ($42.418 million) (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Surge: Q3 2024 revenue increased 1,075% year-over-year, driven by a Fortune 500 healthcare client (increased unit sales and higher pricing) and new Industry 4.0 contracts.
- Gross Margin Turnaround: The company transitioned from a gross loss in Q3 2023 to a gross profit in Q3 2024, attributed to the aforementioned pricing improvements and volume increases.
- Expense Growth: R&D expenses rose 28% QoQ and 15% YoY (YTD) due to new hires, stock-based compensation, and subcontractor costs for I4.0 projects. G&A expenses increased 22% YoY (YTD) due to professional fees and executive bonuses.
- Liquidity Improvement: Cash and cash equivalents increased from $8.9 million (Dec 31, 2023) to $20.9 million (Sept 30, 2024), bolstered by a $10.3 million private placement in July 2024.
Outlook, Risks, and Management Commentary
- Capital Requirements: Management believes current cash resources will fund operations for at least the next 12 months. However, the company expects to continue incurring significant R&D and commercialization costs and will require additional funding to reach profitability.
- Future Revenue: As of September 30, 2024, Remaining Performance Obligations (RPO) totaled approximately $16.0 million. This includes a long-term purchase order exceeding $10 million signed in Q3 2024 with a leading international defense contractor; no revenue has been recognized from this contract yet.
- Personnel Changes: Mr. Ido Molad, VP of Research and Development, intends to step down on November 21, 2024, for personal reasons. He will remain with the company in a different capacity. Mr. Gal Shir has been nominated as acting VP R&D.
- Risks: The company faces risks related to its start-up nature, dependence on a limited number of customers, and the need for future equity financing which may result in dilution.
Investor Verification Checklist
- Customer Concentration: Verify the sustainability of revenue from the single Fortune 500 healthcare client and the specific terms of the new $10M+ defense contract.
- Burn Rate vs. Runway: Confirm the 12-month liquidity runway given the continued operating losses of ~$3M per quarter.
- Stock-Based Compensation: Review the impact of the $1.5M stock-based compensation expense (YTD 2024) on future cash flow and dilution.
- Management Transition: Assess the impact of the VP R&D departure on ongoing product development timelines.
- Warrant Overhang: Note the existence of ~5.76 million outstanding warrants with exercise prices ranging from $5.50 to $10.35.